These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 17486596

  • 1. Botulinum toxin treatment for blepharospasm associated with myasthenia gravis.
    Hara K, Matsuda A, Kitsukawa Y, Tanaka K, Nishizawa M, Tagawa A.
    Mov Disord; 2007 Jul 15; 22(9):1363-4. PubMed ID: 17486596
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Botulinum toxin therapy for blepharospasm in the otolaryngology clinic.
    Lassen LF, Adams J.
    ORL Head Neck Nurs; 1994 Jul 15; 12(3):12-3. PubMed ID: 8564763
    [Abstract] [Full Text] [Related]

  • 4. [Use of botulinum toxin in ophthalmology: current concepts and problems].
    Tapiero B, Robert PY, Adenis JP, Riss I.
    J Fr Ophtalmol; 1997 Jul 15; 20(2):134-45. PubMed ID: 9099272
    [No Abstract] [Full Text] [Related]

  • 5. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
    Bhidayasiri R, Cardoso F, Truong DD.
    Eur J Neurol; 2006 Feb 15; 13 Suppl 1():21-9. PubMed ID: 16417594
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Botulinum toxin therapy: from dreaded biological toxin to standard pharmaceutical].
    Schnider P, Voller B, Moraru K, Auff E.
    Wien Klin Wochenschr; 1999 Oct 29; 111(20):825-9. PubMed ID: 10586486
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical and psychological factors influencing the efficacy of botulinum toxin in the treatment of hemifacial spasm and blepharospasm].
    Burbaud P, Arnaud A, Burbaud A, Lagueny A.
    J Fr Ophtalmol; 1995 Oct 29; 18(12):751-7. PubMed ID: 8745707
    [Abstract] [Full Text] [Related]

  • 10. Dystonic frowning without blepharospasm.
    Hirota N, Hirota M, Mezaki T.
    Parkinsonism Relat Disord; 2008 Nov 29; 14(7):579-80. PubMed ID: 18316230
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Botulinum toxin in movement disorders.
    Papapetropoulos S, Singer C.
    Semin Neurol; 2007 Apr 29; 27(2):183-94. PubMed ID: 17390263
    [Abstract] [Full Text] [Related]

  • 13. Botulinum toxin increases tearing in patients with Sjögren's syndrome: a preliminary report.
    Spiera H, Asbell PA, Simpson DM.
    J Rheumatol; 1997 Sep 29; 24(9):1842-3. PubMed ID: 9292815
    [Abstract] [Full Text] [Related]

  • 14. Blepharospasm and autoimmune diseases.
    Jankovic J, Patten BM.
    Mov Disord; 1987 Sep 29; 2(3):159-63. PubMed ID: 3509774
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey.
    Cossu G, Mereu A, Deriu M, Melis M, Molari A, Melis G, Minafra L, Pisano T, Cianchetti C, Ortu E, Sau G, Aiello I, Fresu M, Marrosu MG, Contu P.
    Mov Disord; 2006 Nov 29; 21(11):2005-8. PubMed ID: 16960861
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Turn/amplitude analysis to assess bulbar muscle wasting in MuSK positive myasthenia.
    Finsterer J.
    Clin Neurophysiol; 2007 May 29; 118(5):1173-4; author reply 1174-5. PubMed ID: 17382588
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.